Pub Date : 2024-10-16DOI: 10.1016/j.jdin.2024.10.001
Jonathan Kantor MD, MSc, MSCE
{"title":"The great automatic grammatizator: On the use and misuse of large language models in scientific and academic writing","authors":"Jonathan Kantor MD, MSc, MSCE","doi":"10.1016/j.jdin.2024.10.001","DOIUrl":"10.1016/j.jdin.2024.10.001","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 79-80"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/j.jdin.2024.09.005
Courtney A. Smith MS , Deeti Pithadia MD , Diana Wang MD, PhD , Marcia Hogeling MD , Carol E. Cheng MD
{"title":"Video synchronous isotretinoin management is associated with lower risk of patient attrition compared to in-person follow-up: A single-center cohort study involving propensity-score matched analysis of patients with acne","authors":"Courtney A. Smith MS , Deeti Pithadia MD , Diana Wang MD, PhD , Marcia Hogeling MD , Carol E. Cheng MD","doi":"10.1016/j.jdin.2024.09.005","DOIUrl":"10.1016/j.jdin.2024.09.005","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 35-37"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-11DOI: 10.1016/j.jdin.2024.09.004
Alim Osman MS , Megan Jayne Ralston MS , Michael Christopher Povelaitis BS , Mariela Mitre MD, PhD
{"title":"COVID-19 infection or vaccination and hidradenitis suppurativa: A systematic review","authors":"Alim Osman MS , Megan Jayne Ralston MS , Michael Christopher Povelaitis BS , Mariela Mitre MD, PhD","doi":"10.1016/j.jdin.2024.09.004","DOIUrl":"10.1016/j.jdin.2024.09.004","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 32-34"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-10DOI: 10.1016/j.jdin.2024.08.023
Shawn Afvari BS , David A. Collet BS , Anjali Goyal BS , Esewi Aifuwa BSE , Avery H. LaChance MD, MPH , Bijan Safai MD, DSc
{"title":"Geospatial analysis of dermatologist distribution and access among US seniors","authors":"Shawn Afvari BS , David A. Collet BS , Anjali Goyal BS , Esewi Aifuwa BSE , Avery H. LaChance MD, MPH , Bijan Safai MD, DSc","doi":"10.1016/j.jdin.2024.08.023","DOIUrl":"10.1016/j.jdin.2024.08.023","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 41-43"},"PeriodicalIF":0.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-10DOI: 10.1016/j.jdin.2024.09.003
Ignacio Alarcón BSc , Javier Arellano MD, MCE, MSc
{"title":"Inverse association between regional solar radiation and hospital discharges due to bullous diseases in Chile: An ecological study","authors":"Ignacio Alarcón BSc , Javier Arellano MD, MCE, MSc","doi":"10.1016/j.jdin.2024.09.003","DOIUrl":"10.1016/j.jdin.2024.09.003","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 38-40"},"PeriodicalIF":0.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication.
Objective
To assess safety and tolerability of SB206 12% in Japanese patients with MC.
Methods
SKN15B01 (JRCT2031230123) was a phase 2, multicenter, single-group, open-label study in Japanese patients ≥2 years old with 3-70 baseline MC lesions. Patients with only periocular MC and/or immunosuppression were excluded. SB206 12% was applied once daily to lesions for 12 weeks. Safety endpoints included adverse events and local skin reactions. Exploratory efficacy endpoints included percentage of patients with complete lesion clearance and lesion count percent change from baseline.
Results
Twenty patients (12 males, 8 females) with mean (range) age of 5.2 (3-13) years and mean (range) baseline lesion counts of 22.5 (8-44). Complete clearance and percent change from baseline at week 12 were 60% and −89.2%, respectively. The most common treatment-related adverse events were application site-erythema (25%, n = 5), -pain (25%, n = 5), -pruritis (25%, n = 5), and -dermatitis (20%, n = 4), all mild/moderate in severity.
Limitations
Single-group study; small sample size.
Conclusion
Safety and efficacy of berdazimer gel, 10.3% in Japanese patients were favorable and consistent with previous studies.
{"title":"The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum","authors":"Makoto Kawashima MD, PhD , Yoshiyuki Kaneko BS , Manami Sawasaki BS , Kyohei Masubuchi BS , Hiroyuki Yasukawa BS , Saki Okada BS , Carolyn Enloe MPH , Carri Geer PhD , Martina Cartwright PhD , Tomoko Maeda-Chubachi MD, PhD , Takeshi Tani BS","doi":"10.1016/j.jdin.2024.09.002","DOIUrl":"10.1016/j.jdin.2024.09.002","url":null,"abstract":"<div><h3>Background</h3><div>Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication.</div></div><div><h3>Objective</h3><div>To assess safety and tolerability of SB206 12% in Japanese patients with MC.</div></div><div><h3>Methods</h3><div>SKN15B01 (JRCT2031230123) was a phase 2, multicenter, single-group, open-label study in Japanese patients ≥2 years old with 3-70 baseline MC lesions. Patients with only periocular MC and/or immunosuppression were excluded. SB206 12% was applied once daily to lesions for 12 weeks. Safety endpoints included adverse events and local skin reactions. Exploratory efficacy endpoints included percentage of patients with complete lesion clearance and lesion count percent change from baseline.</div></div><div><h3>Results</h3><div>Twenty patients (12 males, 8 females) with mean (range) age of 5.2 (3-13) years and mean (range) baseline lesion counts of 22.5 (8-44). Complete clearance and percent change from baseline at week 12 were 60% and −89.2%, respectively. The most common treatment-related adverse events were application site-erythema (25%, <em>n</em> = 5), -pain (25%, <em>n</em> = 5), -pruritis (25%, <em>n</em> = 5), and -dermatitis (20%, <em>n</em> = 4), all mild/moderate in severity.</div></div><div><h3>Limitations</h3><div>Single-group study; small sample size.</div></div><div><h3>Conclusion</h3><div>Safety and efficacy of berdazimer gel, 10.3% in Japanese patients were favorable and consistent with previous studies.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 8-16"},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder that affects palms and soles. Patients suffer significant pain, itching, and daily activity impairment. Guselkumab, an interleukin-23 inhibitor, has been approved for PPP treatment in Japan. However, there is no effective therapy licensed for PPP in Europe and the USA.
Objective
To explore the efficacy and safety of guselkumab in patients with moderate-to-severe PPP in the Caucasian population.
Methods
A multicenter, single-arm, phase II study involving 50 patients with moderate-to-severe PPP treated with 100 mg guselkumab subcutaneously for 24 weeks was conducted (GAP). Primary endpoint was the reduction of palmoplantar-pustulosis psoriasis area and severity index (PPPASI) at week 24 compared to baseline. Secondary endpoints included physician-assessed and patient-reported measures. Serum samples were taken for exploratory studies.
Results
The primary endpoint was met with a significant median PPPASI reduction by 59.6% at week 24 compared to baseline (P < .001). The proportions of patients achieving PPPASI-50 and PPPASI-75 at week 24 were 66.0% and 34.0%, respectively. Median dermatology life quality index dropped from 15 at baseline to 5 at week 24 (P < .001). Week 4 changes in interleukin-19 serum levels predicted week 24 clinical response.
Conclusion
Guselkumab may be a promising therapeutic option for PPP in Caucasian patients.
{"title":"Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study)","authors":"Dagmar Wilsmann-Theis MD, PhD , Selina Patt , Andreas Pinter MD, PhD , Sascha Gerdes MD, PhD , Nina Magnolo MD , Robert Németh PhD , Jennifer Schmitz MSc , Cornelia Paul MD , Matthias Augustin MD, PhD , Petra Staubach MD, PhD , Ansgar Weyergraf MD , Ulrike Hüffmeier MD , Kerstin Wolk PhD , Robert Sabat MD, PhD , Rotraut Mößner MD, PhD","doi":"10.1016/j.jdin.2024.09.001","DOIUrl":"10.1016/j.jdin.2024.09.001","url":null,"abstract":"<div><h3>Background</h3><div>Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder that affects palms and soles. Patients suffer significant pain, itching, and daily activity impairment. Guselkumab, an interleukin-23 inhibitor, has been approved for PPP treatment in Japan. However, there is no effective therapy licensed for PPP in Europe and the USA.</div></div><div><h3>Objective</h3><div>To explore the efficacy and safety of guselkumab in patients with moderate-to-severe PPP in the Caucasian population.</div></div><div><h3>Methods</h3><div>A multicenter, single-arm, phase II study involving 50 patients with moderate-to-severe PPP treated with 100 mg guselkumab subcutaneously for 24 weeks was conducted (GAP). Primary endpoint was the reduction of palmoplantar-pustulosis psoriasis area and severity index (PPPASI) at week 24 compared to baseline. Secondary endpoints included physician-assessed and patient-reported measures. Serum samples were taken for exploratory studies.</div></div><div><h3>Results</h3><div>The primary endpoint was met with a significant median PPPASI reduction by 59.6% at week 24 compared to baseline (<em>P</em> < .001). The proportions of patients achieving PPPASI-50 and PPPASI-75 at week 24 were 66.0% and 34.0%, respectively. Median dermatology life quality index dropped from 15 at baseline to 5 at week 24 (<em>P</em> < .001). Week 4 changes in interleukin-19 serum levels predicted week 24 clinical response.</div></div><div><h3>Conclusion</h3><div>Guselkumab may be a promising therapeutic option for PPP in Caucasian patients.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 69-78"},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.1016/j.jdin.2024.08.015
Gurman S. Dhaliwal MD , Adina Greene BA , Andy Ho BS , Aaron R. Mangold MD , Collin M. Costello MD
{"title":"Incidence of melanoma in situ among racial and ethnic minorities in the United States","authors":"Gurman S. Dhaliwal MD , Adina Greene BA , Andy Ho BS , Aaron R. Mangold MD , Collin M. Costello MD","doi":"10.1016/j.jdin.2024.08.015","DOIUrl":"10.1016/j.jdin.2024.08.015","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 20-21"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号